New Market Report Now Available: China Pharmaceuticals & Healthcare Report Q3 2010
New Market Report Now Available: China Pharmaceuticals & Healthcare Report Q3 2010
Recently published research from Business Monitor International, "China Pharmaceuticals & Healthcare Report Q3 2010", is now available at Fast Market Research
In the Asia Pacific Pharmaceuticals & Healthcare BERs for Q310, China has maintained fourth position of the 16 markets covered in Asia Pacific, with an above average pharmaceutical rating of 61.3. China scores highly for Pharmaceutical Market (67) and Market Risks (67), but is let down by Country Risk (55) and Country Structure (43). In the Asia Pacific matrix of countries, China falls below Australia and Japan, but above Singapore and Taiwan. Globally, China is ranked in 17th position (as is Brazil), falling below the Netherlands and Spain and above Portugal and Poland.
BMI's proprietary Drug Expenditure Forecast Model reveals that the value of China's pharmaceutical market is set to surpass several developed states, including France and Germany, over the next few years. The reasons for this are multi-fold and include an ambitious CNY850bn (US$124.5bn) healthcare reform programme. China plans to widen insurance coverage to include many more of its vast rural population, as well as to build thousands of community healthcare centres over the next three years.
Additionally, the key driver of China's pharmaceutical market over the medium term is the booming economy. Although partially reliant on exports for economic sustenance, considerable domestic consumption means that real GDP growth in 2009 was a respectable 8.7%. Although down against previous years - 2008 (9.0%), 2007 (13.0%) and 2006 (11.6%) - this figure still stands well above the global average of -0.1%.
The reform of regulations on foreign direct investment (FDI) has seen pharmaceutical regulation in particular undergoing considerable change in recent years. Many processes have become increasingly aligned with international norms, making the operating environment increasingly transparent for outside investors.
BMI believes that drugmakers have recognised the opportunities present in China's fast growing pharmaceutical market. In April 2010, Sanofi-Aventis expanded its research and development (R&D) presence in China by opening a new R&D centre. Marc Cluzel, Sanofi's vice president of R&D, said that with the new centre, the company aims to stimulate the development of therapies and health solutions in the region. Additionally, in March 2010, Eli Lilly announced plans to launch 15 new products in China over the next five years. Reuters reports the Indianapolis-based firm's chief executive, John Lechleiter, describing the company's strategy as being 'investing aggressively in China' at a pharmaceutical conference in Shanghai. The shift in investment to an emerging market is invariably linked to austerity plans revealed by European governments, which intend to cut the prices of patented drugs.
For more information or to purchase this report, go to:
- http://www.fastmr.com/prod/71634_china_pharmaceuticals_h ...
Report Table of Contents:
Executive Summary
- China Pharmaceuticals And Healthcare Industry SWOT
- China Political SWOT
- China Economic SWOT
- China Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q310
- Limits of Potential Returns
- Risks to Realisation of Returns
China - Market Summary
- Regulatory Regime
- Pharmaceutical Advertising
- Intellectual Property Issues
- Counterfeit Medicines
- Pricing Regime
- Price Cuts
- Reimbursement Regime
- Other Regulatory Developments
Industry Trends and Developments
- Epidemiology
- Communicable Diseases
- Non-Communicable Diseases
- Healthcare Sector
- Recent Healthcare Sector Developments
- Hospital Sector
- Top Ten Multinationals Operating In China According To 2008 Hospital Sales
- Top Ten Medicines In China According To 2008 Hospital Sales
- China's Hospital Pharmaceutical Market According To Source Of Medicines
- R&D Activity
- Clinical Trials Activity
- Biotechnology Sector
- Active Pharmaceutical Ingredients (APIs)
- Vaccine Sector
- Recent Developments in the Vaccine Sector
- Pharmaceutical Equipment Sector
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: China - Economic Activity, 2007-2014
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Leading OTC Medicine Manufacturers In China According To 2009 Sales
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Top 20 Pharmaceutical Companies In China According To 2008 Sales
- Recent Pharmaceutical Industry Developments
- Traditional Chinese Medicines
- Pharmaceutical Distribution Sector
- China Pharmaceutical Market According To Sales Channel
Company Profiles
- Indigenous Manufacturers
- North China Pharmaceutical Corporation (NCPC)
- China Biopharmaceuticals Holdings (CBH)
- Hubei Biocause Heilen Pharmaceutical
- Aida Pharmaceutical Holdings
- Leading Multinational Companies
- GlaxoSmithKline
- Pfizer
- AstraZeneca
- Merck KGaA
- Sanofi-Aventis
- Novartis
- Roche
- Eli Lilly (Lilly China)
- Merck & Co
- Bayer Schering Pharma
Country Snapshot: China Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables
About Business Monitor International
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Recently published research from Business Monitor International, "China Pharmaceuticals & Healthcare Report Q3 2010", is now available at Fast Market Research
In the Asia Pacific Pharmaceuticals & Healthcare BERs for Q310, China has maintained fourth position of the 16 markets covered in Asia Pacific, with an above average pharmaceutical rating of 61.3. China scores highly for Pharmaceutical Market (67) and Market Risks (67), but is let down by Country Risk (55) and Country Structure (43). In the Asia Pacific matrix of countries, China falls below Australia and Japan, but above Singapore and Taiwan. Globally, China is ranked in 17th position (as is Brazil), falling below the Netherlands and Spain and above Portugal and Poland.
BMI's proprietary Drug Expenditure Forecast Model reveals that the value of China's pharmaceutical market is set to surpass several developed states, including France and Germany, over the next few years. The reasons for this are multi-fold and include an ambitious CNY850bn (US$124.5bn) healthcare reform programme. China plans to widen insurance coverage to include many more of its vast rural population, as well as to build thousands of community healthcare centres over the next three years.
Additionally, the key driver of China's pharmaceutical market over the medium term is the booming economy. Although partially reliant on exports for economic sustenance, considerable domestic consumption means that real GDP growth in 2009 was a respectable 8.7%. Although down against previous years - 2008 (9.0%), 2007 (13.0%) and 2006 (11.6%) - this figure still stands well above the global average of -0.1%.
The reform of regulations on foreign direct investment (FDI) has seen pharmaceutical regulation in particular undergoing considerable change in recent years. Many processes have become increasingly aligned with international norms, making the operating environment increasingly transparent for outside investors.
BMI believes that drugmakers have recognised the opportunities present in China's fast growing pharmaceutical market. In April 2010, Sanofi-Aventis expanded its research and development (R&D) presence in China by opening a new R&D centre. Marc Cluzel, Sanofi's vice president of R&D, said that with the new centre, the company aims to stimulate the development of therapies and health solutions in the region. Additionally, in March 2010, Eli Lilly announced plans to launch 15 new products in China over the next five years. Reuters reports the Indianapolis-based firm's chief executive, John Lechleiter, describing the company's strategy as being 'investing aggressively in China' at a pharmaceutical conference in Shanghai. The shift in investment to an emerging market is invariably linked to austerity plans revealed by European governments, which intend to cut the prices of patented drugs.
For more information or to purchase this report, go to:
- http://www.fastmr.com/prod/71634_china_pharmaceuticals_h ...
Report Table of Contents:
Executive Summary
- China Pharmaceuticals And Healthcare Industry SWOT
- China Political SWOT
- China Economic SWOT
- China Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q310
- Limits of Potential Returns
- Risks to Realisation of Returns
China - Market Summary
- Regulatory Regime
- Pharmaceutical Advertising
- Intellectual Property Issues
- Counterfeit Medicines
- Pricing Regime
- Price Cuts
- Reimbursement Regime
- Other Regulatory Developments
Industry Trends and Developments
- Epidemiology
- Communicable Diseases
- Non-Communicable Diseases
- Healthcare Sector
- Recent Healthcare Sector Developments
- Hospital Sector
- Top Ten Multinationals Operating In China According To 2008 Hospital Sales
- Top Ten Medicines In China According To 2008 Hospital Sales
- China's Hospital Pharmaceutical Market According To Source Of Medicines
- R&D Activity
- Clinical Trials Activity
- Biotechnology Sector
- Active Pharmaceutical Ingredients (APIs)
- Vaccine Sector
- Recent Developments in the Vaccine Sector
- Pharmaceutical Equipment Sector
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: China - Economic Activity, 2007-2014
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Leading OTC Medicine Manufacturers In China According To 2009 Sales
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Top 20 Pharmaceutical Companies In China According To 2008 Sales
- Recent Pharmaceutical Industry Developments
- Traditional Chinese Medicines
- Pharmaceutical Distribution Sector
- China Pharmaceutical Market According To Sales Channel
Company Profiles
- Indigenous Manufacturers
- North China Pharmaceutical Corporation (NCPC)
- China Biopharmaceuticals Holdings (CBH)
- Hubei Biocause Heilen Pharmaceutical
- Aida Pharmaceutical Holdings
- Leading Multinational Companies
- GlaxoSmithKline
- Pfizer
- AstraZeneca
- Merck KGaA
- Sanofi-Aventis
- Novartis
- Roche
- Eli Lilly (Lilly China)
- Merck & Co
- Bayer Schering Pharma
Country Snapshot: China Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Forecast Tables
About Business Monitor International
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- Universal Travel Group Appoints Chief Operating Officer and New Board Members [08 Feb 2012] PR Newswire
© 2005-2012